| 2021 | | Real-world observational study of biosimilars in inflammatory arthritis treatment: a systematic literature review | 김지원, 서창희, 정주양 |
| 2021 | | Systemic immune-inflammation index combined with ferritin can serve as a reliable assessment score for adult-onset Still's disease | 김지원, 김현아, 서창희, 정주양 |
| 2021 | | Lupus low disease activity state achievement is important for reducing adverse outcomes in pregnant patients with systemic lupus erythematosus | 곽동욱, 김지원, 김현아, 서창희, 양정인, 정주양 |
| 2021 | | An update on the pathogenic role of neutrophils in systemic juvenile idiopathic arthritis and adult-onset still’s disease | 김지원, 김현아, 서창희, 안미현, 정주양 |
| 2021 | | Salivary immunoglobulin gamma-3 chain c is a promising noninvasive biomarker for systemic lupus erythematosus | 김현아, 서창희, 정주양 |
| 2021 | | Toll‐like receptor signaling inhibitory peptide improves inflammation in animal model and human systemic lupus erythematosus | 서창희 |
| 2021 | | Salivary Biomarkers in Patients with Sjögren's Syndrome-A Systematic Review | 김지원, 김현아, 서창희, 정주양 |
| 2021 | | Meta-analysis of 208370 East Asians identifies 113 susceptibility loci for systemic lupus erythematosus | 서창희 |
| 2021 | | Impact of infliximab biosimilar ct-p13 dose and infusion interval on real-world drug survival and effectiveness in patients with ankylosing spondylitis | 서창희 |
| 2021 | | Anti-inflammatory effects of low-dose glucocorticoids compensate for their detrimental effects on bone mineral density in patients with rheumatoid arthritis | 김지원, 김현아, 서창희, 정주양 |
| 2021 | | The assessment of muscle mass and function in patients with long-standing rheumatoid arthritis | 김지원, 김춘자, 김현아, 서창희, 정주양 |
| 2021 | | Comparison of Retention Rates Between Tumor Necrosis Factor-α Inhibitors in Patients With Ankylosing Spondylitis: Data From the Korean College of Rheumatology Biologics Registry | 김현아 |
| 2021 | | Factors Determining Retreatment Time Interval of Rituximab in Korean Patients With Rheumatoid Arthritis | 김지원, 김현아, 서창희, 정주양 |
| 2021 | | Effectiveness and safety of biologic and targeted synthetic disease-modifying anti-rheumatic drugs in elderly patients with rheumatoid arthritis: Real-world data from the KOBIO registry | 김현아 |
| 2021 | | Four-year follow-up of atherogenicity in rheumatoid arthritis patients: from the nationwide Korean College of Rheumatology Biologics Registry | 김현아 |
| 2021 | | Biologic therapy for amyloid A amyloidosis secondary to rheumatoid arthritis treated with interleukin 6 therapy: Case report and review of literature | 김영배, 김지원, 김현아, 서창희, 정주양 |
| 2021 | | Association of TLR 9 gene polymorphisms with remission in patients with rheumatoid arthritis receiving TNF-α inhibitors and development of machine learning models | 정주양 |
| 2021 | | KOBIO, the first web-based Korean biologics registry operated with a unified platform among distinct disease entities | 김현아 |
| 2021 | | Intravenous Administration of Toll-Like Receptor Inhibitory Peptide 1 is Effective for the Treatment of Systemic Lupus Erythematosus in a Mus musculus Model | 서창희 |
| 2021 | | Health-related Quality of Life Outcomes of Adalimumab for Patients with Rheumatoid Arthritis in Korea | 김현아 |
